Andrea Basso - Concepedia

Author

Andrea Basso

Istituto Nazionale di Riposo e Cura per Anziani ORCID

Also Known As

A BASSO, A Basso, A. BASSO, A. Basso, A. D. Basso, Andrea Basso, Andrea D Basso, Andrea D. Basso, Angelica Basso, Basso, A.D.

151

Publications

Citations

H-Index

134

Concepts

All Affiliations

Istituto Nazionale di Riposo e Cura per Anziani Istituti di Ricovero e Cura a Carattere Scientifico Memorial Sloan Kettering Cancer Center Merck & Co., Inc., Rahway, NJ, USA (United States)University of Bologna

About

Andrea Basso is an author at Istituto Nazionale di Riposo e Cura per Anziani specializing in medicine, pharmacology, and cell biology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	25	50	4.6K
2	Natural Sciences	7	7	183
3	Health Sciences	4	4	235
4	Public Health	2	2	81
5	Engineering	1	1	26

Andrea Basso

Publications

6.6K

Citations

H-Index

Page 1

	Year	Citations
BRAF mutation predicts sensitivity to MEK inhibition David B. Solit, Levi A. Garraway, Christine A. Pratilas, Nature Signal TransductionBraf MutationGenetic DisorderMedicineGenetics	2005	1.3K
Akt Forms an Intracellular Complex with Heat Shock Protein 90 (Hsp90) and Cdc37 and Is Destabilized by Inhibitors of Hsp90 Function Andrea Basso, David B. Solit, Gabriela Chiosis, Journal of Biological Chemistry	2002	620
The tyrosine kinase inhibitor ZD1839 ("Iressa") inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cells. Mark M. Moasser, Andrea Basso, Steven D. Averbuch, PubMed Breast OncologyHer2-driven SignalingTumor BiologyTumor SensitivitySignaling Pathway	2001	508
Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors Roberto Bianco, Incheol Shin, Christoph A. Ritter, Oncogene MedicineReceptor Tyrosine KinasePharmacologyAntitumor ActionTumor Suppressor	2003	452
V600E B-Raf requires the Hsp90 chaperone for stability and is degraded in response to Hsp90 inhibitors Olivera M. Grbovic, Andrea Basso, Ayana Sawai, Proceedings of the National Academy of Sciences	2005	306
Resistance to gefitinib in PTEN-null HER-overexpressing tumor cells can be overcome through restoration of PTEN function or pharmacologic modulation of constitutive phosphatidylinositol 3'-kinase/Akt pathway signaling. Qing‐Bai She, David B. Solit, Andrea Basso, PubMed	2003	290
Inhibition of heat shock protein 90 function down-regulates Akt kinase and sensitizes tumors to Taxol. David B. Solit, Andrea Basso, Adam B. Olshen, Cancer Research Chemoprevention StrategyApoptosisCell DeathCancer BiologyTumor Biology	2003	277
Ansamycin antibiotics inhibit Akt activation and cyclin D expression in breast cancer cells that overexpress HER2 Andrea Basso, David B. Solit, Pamela N. Münster, Oncogene Tumor BiologyBreast OncologyOncologyMedicineAkt Activation	2002	269
Modulation of Hsp90 function by ansamycins sensitizes breast cancer cells to chemotherapy-induced apoptosis in an RB- and schedule-dependent manner. See: E. A. Sausville, Combining cytotoxics and 17-allylamino, 17-demethoxygeldanamycin: sequence and tumor biology matters, Clin. Cancer Res., 7: 2155-2158, 2001. Pamela N. Münster, Andrea Basso, D. Solit, PubMed Chemoprevention StrategyEnvironmental StressApoptosisImmunologyCell Death	2001	173
Plasma copper/zinc ratio: an inflammatory/nutritional biomarker as predictor of all-cause mortality in elderly population Marco Malavolta, Robertina Giacconi, Francesco Piacenza, Biogerontology InflammationMetabolic SyndromeAll-cause MortalityAgingGeriatrics	2009	172

Page 1